Navigation Links
AutoImmune Inc. Reports 2008 Second Quarter Financial Results
Date:8/7/2008

PASADENA, Calif., Aug. 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Pink Sheets: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008, compared with a net loss of $62,000, or break even per share basic and diluted, for the three months ended June 30, 2007. For the six months ended June 30, 2008, the net loss was $193,000, or $0.01 per share basic and diluted, compared with net loss of $54,000, or break even per share basic and diluted for the same period in 2007. As of June 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC met our expectations during the second quarter." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS sublicensed its rights in this product to Eli Lilly and Company and subsequently stated that the only results they expect to release in 2008 from an upcoming interim analysis on the first 200 patients in its pivotal phase II/III trial evaluating MBP8298 for treatment of secondary progressive multiple sclerosis will be those related to safety and/or futility. A full analysis of the trial data should be available during the second half of 2009.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended June 30, Six months ended June 30,

2007 2008 2007 2008

Revenue $63,000 $101,000 $160,000 $168,000

Costs and expenses:

Cost of product

revenue 2,000 16,000 11,000 28,000

Research and

development 58,000 48,000 88,000 90,000

Selling, general

and administrative 184,000 181,000 369,000 386,000

Total costs

and expenses 244,000 245,000 468,000 504,000

Interest income 113,000 60,000 223,000 144,000

Minority interest

in joint venture 6,000 (2,000) 6,000 (1,000)

Other income - - 25,000 0

119,000 58,000 254,000 143,000

Net loss ($62,000) ($86,000) ($54,000) ($193,000)

Net loss per share -

basic ($0.00) ($0.01) ($0.00) ($0.01)

Net loss per share -

diluted ($0.00) ($0.01) ($0.00) ($0.01)

Weighted average

common shares

outstanding -

basic 16,979,623 16,999,623 16,961,344 16,998,414

Weighted average

common shares

outstanding -

diluted 16,979,623 16,999,623 16,961,344 16,998,414

CONDENSED BALANCE SHEET

(Unaudited)

December 31, June 30,

2007 2008

Cash and marketable securities $8,804,000 $8,590,000

Other current assets 167,000 137,000

Total assets $8,971,000 $8,727,000

Current liabilities $128,000 $119,000

Minority interest in joint venture 11,000 19,000

Total stockholders' equity 8,832,000 8,589,000

Total liabilities and equity $8,971,000 $8,727,000


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. Isis Reports Financial Results and Highlights for Second Quarter of 2008
6. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. Caliper Life Sciences Reports Second Quarter 2008 Results
9. Watson Pharmaceuticals Reports Second Quarter 2008 Results
10. EntreMed Reports Second Quarter 2008 Financial Results
11. Transgenomic Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... -- Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held advanced ... technologies, today announced that it has been accepted into ... . Shawn Glinter , Founder ... are excited to become part of the JLABS @ ... to be the first Tennessee -based ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 that ... test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for ... NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/25/2017)... ... , ... As part of the Stago EdVantage Virtual University Virtual ... in order to illuminate this clinical problem for people unfamiliar with the topic. , ... a high degree of morbidity and mortality. DIC is a confusing disorder from both ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... , Covalent’s Analytical Services unit provides high-quality data to clients, both ... 24 hours of receipt. There are no price premiums, and customers are welcome ...
Breaking Biology Technology:
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):